Biochemical Recurrence Drops With PSMA-PET/CT Before SRT

WEDNESDAY, Feb. 23, 2022 (HealthDay News) — For patients with prostate cancer, restaging prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) for biochemical recurrence performed prior to initiating local salvage radiation therapy (SRT) is associated with improved oncological outcomes, according to a study published online Jan. 22 in European Urology Oncology.

Dennie Meijer, from the Amsterdam University Medical Center, and colleagues compared the oncological outcomes of a patient cohort that underwent and did not undergo PSMA-PET/CT prior to SRT (298 and 312 patients, respectively). After matching, 216 patients were included (108 in each cohort).

The researchers found that 21% of the patients without PSMA-PET/CT prior to SRT had biochemical progression of disease at one year after SRT compared with 8% who underwent restaging PSMA-PET/CT before SRT. Selecting patients via PSMA-PET/CT imaging for restaging prior to SRT led to a relative risk reduction of 62% for developing biochemical progression at one year. Compared with patients who did not undergo PSMA-PET/CT, those who underwent PSMA-PET/CT restaging had significantly improved biochemical progression-free survival (hazard ratio=1.79).

“With these findings, we demonstrated that selecting patients for local salvage treatment, without metastatic disease on restaging PSMA-PET/CT, improves oncological outcomes in this selected series of patients,” the authors write.

Abstract/Full Text